CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-21 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) | −20 | 316,725 | ||
| 2023-12-21 | Heyman Richard A. Director | Sale 10b5-1 | −7 | $13.00 | $91 | 147,448 |
| 2023-12-21 | Heyman Richard A. Director | Sale 10b5-1 | −6 | $13.00 | $78 | 29,251 |
| 2023-12-20 | Kintz Samuel President and CEO | Option exercise 10b5-1 | +7,779 | $1.12 | $9K | 7,779 |
| 2023-12-20 | Kintz Samuel President and CEO | Sale 10b5-1 | −7,779 | $13.01 | $101K | 0 |
| 2023-12-20 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −7,779 | 316,745 | ||
| 2023-12-20 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +8,688 | $1.12 | $10K | 8,688 |
| 2023-12-20 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −8,688 | $13.01 | $113K | 0 |
| 2023-12-20 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −8,688 | 315,116 | ||
| 2023-12-20 | Heyman Richard A. Director | Sale 10b5-1 | −2,110 | $13.02 | $27K | 147,455 |
| 2023-12-20 | Heyman Richard A. Director | Sale 10b5-1 | −1,915 | $13.02 | $25K | 29,257 |
| 2023-12-19 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +200 | $1.12 | $224 | 200 |
| 2023-12-19 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −200 | $13.00 | $3K | 0 |
| 2023-12-19 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −200 | 323,804 | ||
| 2023-12-19 | Heyman Richard A. Director | Sale 10b5-1 | −255 | $13.00 | $3K | 149,565 |
| 2023-11-03 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +8,546 | $1.12 | $10K | 8,546 |
| 2023-11-03 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −8,546 | $13.08 | $112K | 0 |
| 2023-11-03 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −8,546 | 324,004 | ||
| 2023-11-03 | Kintz Samuel President and CEO | Option exercise 10b5-1 | +8,026 | $1.12 | $9K | 8,026 |
| 2023-11-03 | Kintz Samuel President and CEO | Sale 10b5-1 | −8,026 | $13.08 | $105K | 0 |
Page 29 of 37 · 724 trades